Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.

Sophie CousinCoralie CantarelJean-Philippe GueganCarlos Alberto Gomez RocaJean-Philippe MetgesAntoine AdenisSimon PernotJean-Yves BlayMichèle KindCéline AuzanneauFrançois Le LoarerIsabelle SoubeyranAlban BessedeAntoine Italiano

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

The combination of regorafenib + avelumab mobilizes antitumor immunity in a subset of patients with microsatellite stable colorectal cancer. Computational pathology through quantification of immune cell infiltration may improve patient selection for further studies investigating this approach.

Keyphrases

open label
metastatic colorectal cancer
clinical trial
case report
phase iii
phase ii study
genetic diversity
study protocol
randomized controlled trial
squamous cell carcinoma
radiation therapy